Literature DB >> 8017890

Natural history of multiple sclerosis.

B G Weinshenker1.   

Abstract

Multiple sclerosis (MS) is the most common idiopathic inflammatory disease of the central nervous system. The distinction between MS and other benign or fulminant inflammatory demyelinating disorders is based on quantitative, rather than qualitative, differences in chronicity and severity. Primary progressive MS may differ from relapsing-remitting MS in MRI lesion frequency, immunogenetic profile, responsiveness to immunosuppressive treatment, and histology. In 60% of patients, MS begins as a relapsing-remitting disease and evolves secondarily into a progressive neurological illness. Life expectancy is not substantially altered in patients with MS, particularly in the early years of the illness. The rate of suicide has been reported to be increased sevenfold in MS patients. Up to 40% of patients with attacks severe enough to render them nonambulatory may not recover. At 15 years from MS onset, 50% of patients are disabled to the point at which they at least require a cane to walk a half block. Early age at onset, female sex, relapsing-remitting course at onset, and perhaps optic neuritis or sensory symptoms at onset and relatively few attacks in the first two years are associated with a favorable course.

Entities:  

Mesh:

Year:  1994        PMID: 8017890     DOI: 10.1002/ana.410360704

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  65 in total

Review 1.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

2.  Brain metabolite proton T2 mapping at 3.0 T in relapsing-remitting multiple sclerosis.

Authors:  Ivan I Kirov; Songtao Liu; Roman Fleysher; Lazar Fleysher; James S Babb; Joseph Herbert; Oded Gonen
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

3.  Interferon-gamma activated calcium influx in peripheral blood lymphocytes from patients with primary and secondary progressive multiple sclerosis.

Authors:  G Martino; E Brambilla; M Filippi; V Martinelli; B Colombo; M Rodegher; G Comi; L M Grimaldi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

4.  Clinical characteristics and long term prognosis in early onset multiple sclerosis.

Authors:  Olivier Deryck; Pierre Ketelaer; Bénédicte Dubois
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

Review 5.  Pharmacological treatment of early multiple sclerosis.

Authors:  Olaf Stüve; Jeffrey L Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.

Authors:  Lutz Achtnichts; Oded Gonen; Daniel J Rigotti; James S Babb; Yvonne Naegelin; Iris-Katharina Penner; Kerstin Bendfeldt; Jochen Hirsch; Michael Amann; Ludwig Kappos; Achim Gass
Journal:  Eur J Radiol       Date:  2013-09-04       Impact factor: 3.528

Review 7.  Mitoxantrone: a review of its use in multiple sclerosis.

Authors:  Lesley J Scott; David P Figgitt
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  XY sex chromosome complement, compared with XX, in the CNS confers greater neurodegeneration during experimental autoimmune encephalomyelitis.

Authors:  Sienmi Du; Noriko Itoh; Sahar Askarinam; Haley Hill; Arthur P Arnold; Rhonda R Voskuhl
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

9.  Glatiramer acetate guards against rapid memory decline during relapsing-remitting experimental autoimmune encephalomyelitis.

Authors:  Patrizia LoPresti
Journal:  Neurochem Res       Date:  2014-12-07       Impact factor: 3.996

10.  Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis.

Authors:  Belinda S Y Li; Juleiga Regal; Brian J Soher; Lois J Mannon; Robert I Grossman; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.